未找到相关数据
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
被引：14
作者：
Janku, Filip
Iyer, Gopa
Spreafico, Anna
Yamamoto, Noboru
Bang, Yung-Jue
Elez, Elena
De Jonge, Maja J.
Groen, Harry J. M.
Marme, Frederik
Gollmer, Kathrin
St-Pierre, Annie
Melendez, Maritza
Mais, Anna
Nauwelaertsx, Heidi
Nauwelaerts, Heidi
Stammberger, Uz M.
Dummer, Reinhard
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea
[6] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[7] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[8] Erasmus MC Canc Inst, Rotterdam, Netherlands
[9] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[10] Univ Klinikum Heidelberg, Allgemeine Frauenheilkunde & Geburtshilfe, Heidelberg, Germany
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharma AG Hexal AG, Basel, Switzerland
[13] Univ Zurich Hosp, Zurich, Switzerland
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2586
引用
收藏
页数：1
相关论文